A Maryland truck driver suffered an “eye stroke” that left him blind, first in one eye and then the other.
A Louisiana woman vomited for weeks before being diagnosed with a brain dysfunction typically caused by a vitamin deficiency.
An Oklahoma real estate agent heard her colon pop as it ruptured while she drove her granddaughter home from a softball game. “My colon blew up. Literally blew up,” she said.
All three have filed lawsuits that blame the popular class of weight-loss drugs known as GLP-1 receptor agonists, which include Ozempic, Wegovy and Mounjaro, and they’re part of a growing number of lawsuits alleging the drugs’ makers failed to sufficiently warn of the risk of certain severe injuries.
The suits come as the use of the blockbuster drugs has skyrocketed, embraced by millions of Americans to manage diabetes, lower the risk of heart disease and lose weight. The drugs, which mimic a hormone that slows digestion, triggers insulin and helps people feel full longer, cut America’s stubbornly high obesity rates – for the first time in more than a decade – and show promise in aiding a range of conditions from kidney disease to drug addiction.